SHANGHAI, China, November 23, 2022 - Ping An-Shionogi Co., Ltd. (Head Office: Shanghai, China; Chairman and CEO: Tatsumori Yoshida) today announced that the parent company, Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi"), announced that Xocova® (Generic name: Ensitrelvir Fumaric acid, Code No.: S-217622), a novel anti-SARS-CoV-2 drug for COVID-19 obtained emergency regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan under the emergency regulatory approval system. In addition, a contract with the MHLW for the Japanese government to purchase 1 million courses of Xocova® is now effective in accordance with the basic agreement for domestic supply of Xocova® signed by Shionogi and the MHLW in March 2022. Please refer to the original press release by Shionogi for details.

Original press release

Xocova® (Ensitrelvir Fumaric Acid) Tablets 125mg Approved in Japan for the Treatment of SARS-CoV-2 Infection, under the Emergency Regulatory Approval System|News|Shionogi Co., Ltd.